In PMCare’s 2025 panel data, the average GP panel visit cost RM134 — RM34 for the doctor’s time, RM100 for the medication. That RM34 consultation fee sits below the old fee schedule ceiling, paid at a rate the doctor’s own professional body calls inadequate, and its regulatory floor has not moved since 1992. The visit takes perhaps fifteen minutes. The doctor listens, examines, prescribes, and sends the patient home.

Come back a month later, sicker, and the same problem now costs RM9,289 — the average private hospital admission in Malaysia, according to PMCare’s own 2024 data. Not a worst case, not a cancer admission, not an ICU stay. The average. The bill will include a ward fee, nursing charges, consumables itemised to the surgical glove, medication marked up from its panel price, and a doctor’s professional fee that will be, as a share of the total, comparatively small. The gap between RM134 and RM9,289 captures the distortion at the heart of the system: the cheapest point of medical intervention has spent decades under pricing constraints, while costs further downstream have continued to rise.

Hospitals have been allowed to reprice every year. Clinics have not been allowed to reprice at all. That is not a market finding its level. It is a regulatory choice, made once, and never revisited until a fee schedule three decades old finally became impossible to ignore.

Only doctors’ professional fees are regulated. The rest of the bill is not.

The result is a system that regulates most tightly where costs are already lowest, leaves pricing freedom where bills are largest, and is running short of the workforce needed to make the low-cost alternative actually available.

This piece is about that gap, and about the system most Malaysians actually fall back on when private care becomes unaffordable — what it costs, and why it is under real strain.

What is actually rising, and by how much

Aon’s 2026 Global Medical Trend Rates Report puts Malaysia’s gross medical trend rate at 16% for 2026, up from 15% in 2025 — above Thailand (14.8%), the Philippines (14%), Singapore (13%) and Vietnam (12.2%), behind only Indonesia (16.9%), and well above the regional average of 11.3%.

Not everyone accepts the 15–16% figure at face value, and the objection is worth taking seriously rather than smoothing over. Dr Kuljit Singh, president of the Association of Private Hospitals Malaysia, has said publicly that the widely cited figure overstates true price growth because it is derived from insurance claims data, which conflates genuine price increases with rising utilisation — more procedures, more admissions, more expensive technology used more often — rather than measuring the price of a given treatment over time.

That is a fair methodological point, and it does not change the conclusion much. PwC’s own analysis separately finds that insurers’ cumulative medical claims cost rose 56% between 2021 and 2023 alone — a figure calculated independently of the annual trend surveys, and one that outpaces premium growth by a wide enough margin that the claims-versus-utilisation distinction stops mattering much to the person paying the bill. APHM’s own Factbook 2024 offers a different data point — average inpatient bills rose 4% annually between 2020 and 2023 — but this measures hospital billing rather than total medical cost, and APHM has not formally proposed it as a replacement for the national figure. The objection is noted on the record; the alternative measure is not.

Frozen since 1992

Here is the number that makes the inflation figures worse than they look in isolation. Private GP consultation fees in Malaysia are set under the Seventh Schedule of the Private Healthcare Facilities and Services Act 1998 (Act 586). The range — RM10 to RM35 — was originally proposed by MMA itself in 1992, carried into the Act’s regulations in 2006, and then simply left there. For close to two decades MMA described the schedule as stagnant and pressed for a review. Nothing moved.

The Health Minister confirmed in 2025 that a review was under way, noting the rates had not been revised since 2006 — which understates the age of the underlying figures by fourteen years, since 2006 was merely when the 1992 numbers were gazetted, not when they were set.

Budget 2026 delivered a partial answer. The ceiling rose from RM35 to RM80, gazetted and effective from April 2026 — the first revision in the schedule’s history. But the floor stayed at RM10. MMA called keeping it “deeply disappointing,” and the practical effect on what GPs are actually paid has not followed the ceiling upward. PMCare, one of Malaysia’s larger TPAs, told CodeBlue in November 2025 that it paid panel GPs a nationwide average of RM34 for consultation and RM100 for medication — RM134 in total, with the consultation component alone sitting well below even the old RM35 ceiling. And in August 2026, a new insurer product entered the market capping GP visits at RM50 for both consultation and medication combined — a figure MMA president Dr R. Arasu noted was already considered inadequate when Selangor’s Skim Peduli Sihat used it in 2018, and was subsequently raised to RM70. The RM80 regulatory ceiling and the RM34 consultation rate a GP actually receives are not in conflict with each other. They coexist.

Put the two facts together. Medical claims costs have recently been rising at rates approaching 15–16% a year — a figure that combines genuine price increases with rising utilisation and treatment intensity, but one whose direction is not in dispute. Primary care, the part of the system best placed to catch a problem early and cheaply, has been legally prevented from doing more than gesture at keeping pace. Sustained underpricing risks making independent primary care less viable, compressing consultation time and weakening the incentive to manage complex patients in the community rather than refer them onward. Either way, the burden that primary care could have absorbed gets pushed downstream — and shows up on a hospital bill.

The bill inside the bill

The GP fee freeze is a story about primary care pricing. Most patient grievances about private healthcare cost sit somewhere else entirely — not in the consultation fee, but in how a hospital bill is actually built once someone is admitted.

The clearest illustration is also one of the more public ones. Mark O’Dell, chief executive of the Life Insurance Association of Malaysia, shared his own itemised bill for a minor hernia operation — ninety-five separate line items across thirteen categories, totalling RM18,837.55. Equipment came to RM3,850, consignment supplies RM3,189, medication RM2,607, room and board RM2,508. Doctors’ fees, at RM2,621, were a comparatively small share of the total. Individual disposables were priced down to the item: a digital blood pressure monitor at RM53.60, a pulse oximeter at RM57.40.

A second, separately reported case follows a similar shape at a different hospital. A family member described a routine cataract day-surgery bill in which basic consumables — alcohol swabs, surgical gloves, face masks — were charged, in the complainant’s account, at rates bearing no resemblance to their actual cost.

Two cases cannot establish the prevalence of such charging practices, but they illustrate why hospital billing has become a focus of public concern.

This is a live regulatory question, not just a pattern of anecdotes. MOH signalled in 2025 that private clinics should move toward itemised billing, and the profession’s own representative body pushed back hard: FPMPAM’s president called the move a “gross overreach,” warning that itemising every disposable and instrument — gloves, a thermometer, a blood pressure cuff — would more likely push total charges up than deliver the transparency regulators intended. An itemised bill can tell a patient what was charged. It cannot tell the patient whether the charge was fair.

Separately, both the Galen Centre and FOMCA have called for an independent commission to regulate hospital charges beyond the doctor’s own fee — consumables, devices, diagnostic tests, facility charges — through standardised, bundled billing rather than itemisation alone. Galen Centre chief executive Azrul Mohd Khalib put the underlying complaint plainly: Malaysians are “squeezed between unregulated hospital bills, repricing and unreasonable application of private health insurance.”

The clearest evidence on where hospital costs actually originate came from Malaysia’s own Public Accounts Committee, reporting in June 2026: doctors’ professional fees — capped since 2006 and adjusted only once since — are not the primary cost driver. Unregulated non-professional charges are: consumables, implants, diagnostics, marked-up pharmaceuticals. DRG-style bundling, due to begin phased rollout from January 2027, should apply to that unregulated portion of the bill. Folding professional fees into a hospital-administered bundle risks letting facility administrators, not clinicians, decide how much of a fixed payout a doctor receives — and gives hospitals a direct incentive to compress that share to protect their own margins.

The safety valve, and why it is straining

Put next to the GP fee freeze, the two findings point in different directions on the same underlying question. GP consultation fees have been legally prevented from repricing for thirty-three years under the Seventh Schedule of the Private Healthcare Facilities and Services Act. Hospital non-professional charges — consumables, implants, diagnostics, facility fees — have no equivalent ceiling at all under the same Act, and the current push for itemisation risks making the bill longer rather than the total smaller, unless it is paired with the kind of bundling both consumer and policy bodies are now asking for.

Malaysia’s public hospitals and clinics are heavily subsidised, to a degree that looks almost unreal next to the private figures above. A Ministry of Health fee schedule puts outpatient consultation for citizens at RM1 to RM5, specialist clinic follow-up at around RM5, and third-class ward stays at as little as RM3 a night — against private GP fees now running RM10 to RM80, and private ward rates of RM300 to RM1,500 a night. On paper, the public system is not merely cheaper. The nominal patient charge can be tens or even hundreds of times lower.

That is the safety valve working as designed. The strain shows up in how long it takes to use it. A physician writing in CodeBlue in February 2026 described worsening waiting times at government hospital outpatient clinics, attributing it partly to medical officers being repeatedly transferred or made to “float” across departments, disrupting continuity, while specialists are pulled in to act as MOs simply to clear the backlog.

The manpower picture behind that is concrete. MCA’s health bureau chief highlighted conditions at Hospital Tengku Ampuan Rahimah in Klang, where surgical clinics were reportedly staffed by a single medical officer seeing 30 to 40 patients a session — and pointed to a housemanship shortfall as one root cause: MMA data presented to the Parliamentary Special Select Committee shows MOH vacancies grew from 10,419 in 2017 to 54,362 in 2024, while the filling rate fell from 96% to 83%. In the same period, 3,494 doctors left the ministry between 2019 and 2023 alone — 2,385 medical officers and 1,109 specialists. MMA president Datuk Dr Thirunavukarasu Rajoo, speaking on 31 August 2026, was direct about what that means: creating posts alone will not solve the problem.

This is not a new complaint. Penang Institute’s own policy review attributes long queues in Malaysian public hospitals to three compounding causes: rising demand for subsidised care, a supply of healthcare that has not kept pace or is unevenly distributed, and system inefficiencies that sit on top of both.

So the honest picture is not “private care is unaffordable and public care is the answer.” It is that Malaysia runs two systems side by side — one expensive and reasonably fast, one extremely cheap and increasingly slow — and the pressure driving people out of the second and into the first is increasingly a workforce problem as much as a capacity problem. A country simultaneously losing doctors to emigration, while asking the doctors who remain to run surgical clinics of thirty to forty patients each, is not short of demand for its cheap option. It is short of the people needed to deliver it at the pace demand requires.

So what would actually help

1. Raise the floor, not just the ceiling — and close the contracting gap. Raising the statutory floor addresses the legal minimum, but the real problem is that TPAs negotiate panel rates independently of the schedule. PMCare’s own data shows the average panel GP consultation was paid RM34 in 2025 — below even the old RM35 ceiling — suggesting the schedule has not constrained TPA contracting in practice. A meaningful floor revision therefore needs to address the relationship between the statutory fee schedule and TPA panel contracts; otherwise the regulated floor risks becoming a number the contracting market can route around. That means extending regulatory oversight to what MCOs and TPAs may offer panel doctors — not just what facilities may charge patients.
2. Show what is actually driving medical-cost growth. The claims-based 15–16% figure conflates price with utilisation, and that objection is answerable with data the insurers and MOH both hold. A decomposed, published figure would let the public judge whether the driver is price, volume, or both.
3. Fix the public-sector workforce bottleneck. A single medical officer covering thirty to forty patients a surgical clinic session is not a staffing inconvenience. Fixing intake, retention and burnout in the public workforce would do more for waiting times than most of the administrative reforms proposed alongside it.
4. Regulate and bundle non-professional hospital charges. If the cost growth is occurring predominantly in the unregulated part of the bill, reform should begin there — not by squeezing the part that is already capped. Malaysia’s own Public Accounts Committee has confirmed exactly that: doctors’ professional fees are not the primary driver; consumables, implants, diagnostics and pharmaceuticals are. DRG-style bundling from January 2027 should apply to that unregulated portion — not to professional fees, which belong outside any hospital-administered bundle.

In short

A GP consultation fee frozen for thirty-three years while medical claims costs have recently been rising at rates approaching 15–16% a year is not two separate stories. It is one story about where the distortion of a broken pricing structure ends up landing — on the hospital bill, on the person who could not get seen early and cheaply enough to avoid it, and on the public system that is supposed to catch everyone the market leaves behind.

That system is, on paper, one of the most affordable in the region. It is also a ministry where 3,494 doctors walked out between 2019 and 2023, where vacancies grew from 10,419 to 54,362 in seven years, and where MMA’s own president has told Parliament that creating more posts will not, by itself, fix any of it.

Cheap and available are not the same thing. The gap between them is a policy choice — the same kind of choice that kept a fee schedule frozen for thirty-three years, and the same kind of choice that could change it.